Sarepta Therapeutics, Inc. Faces Securities Lawsuit Over Alleged Misstatements

Shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) who suffered losses between June 22, 2023, and June 24, 2025, may seek recovery under the federal securities laws. A class action lawsuit was filed against the company, alleging that defendants made false statements and/or concealed the safety risks of ELEVIDYS, a prescription gene therapy for Duchenne. The complaint alleges that the defendants misrepresented the severity of adverse events from ELEVIDYS treatment, which led to regulatory scrutiny and increased risk for the therapy's approvals.

Key Takeaways:

• A class action securities lawsuit was filed against Sarepta Therapeutics, Inc. alleging securities fraud between June 22, 2023, and June 24, 2025.
• The complaint alleges that defendants made false statements and/or concealed the safety risks of ELEVIDYS, including severe side effects that were not detected in trial regimes and protocols.
• The lawsuit claims that defendants misled investors by making positive statements about the therapy, while omitting the risks associated with it.
• Shareholders who suffered losses during the relevant time frame may seek recovery under the federal securities laws.

Statistics:

• The lawsuit seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between June 22, 2023, and June 24, 2025.
• Sarepta Therapeutics, Inc. is a biotechnology company that develops gene therapies, including ELEVIDYS for Duchenne.
• The U.S. Securities and Exchange Commission (SEC) defines securities fraud as conduct that involves a false or misleading statement or omission that affects a security's value.

Sources:

• Newsfile Corp. press release, July 21, 2025
• https://zlk.com/pslra-1/sarepta-lawsuit-submission-form?prid=157432&wire=5
• Levi & Korsinsky LLP website